Analgesic Solutions is pleased to announce the hiring of three new employees in April
Andrea Licari joins the team as the VP, Development & Operations. Andrea was most recently Chief Operating Officer at Modus, a Massachusetts-based start-up medical device company. Prior to that she was COO at Inflexxion, a privately held company that develops scientifically based, interactive technologies to collect and analyze clinical data to improve care and inform public policy. Andrea will head up all commercial operations including the development and distribution of our proprietary tools and trainings as well as our specialty clinical trials offerings.
Dave Varon joins Analgesic in the role of Principal Data Engineer. Dave will be instrumental in overseeing product deliverables and services within the Quantitative Data Surveillance System (QDSS). Dave was most recently the Scientific Technical Leader-Translational Clinical Oncology at Novartis Institute. His years of experience include Software Engineer at Astra Zeneca, Systems Analyst at Fidelity as well as other software roles.
Molly Spence comes to Analgesic Solutions in the role of Business Development Associate. Her marketing background and experience will aid her in assisting in several important aresa, including the proposal development process, lead generation, social media and marketing efforts. In her former position, Molly worked as a Tradeshow Specialist at Abiomed. Prior to that, she worked at Exact Sciences as a Marketing Specialist.
Analgesic Solutions, LLC, founded in 2006, is a privately held company focused on increasing assay sensitivity in the conduct of pain clinical trials through consulting, innovative tools and technology, and training. Our team, with Nathaniel Katz M.D., M.S., serving as our foremost expert, helps clients develop and commercialize better treatments for pain. With hundreds of projects completed and ongoing collaborations with regulatory authorities, Analgesic Solutions is the expert at identifying and mitigating the random and systematic errors that lead to negative clinical trials.